Gilead Sciences, Inc. (GILD) Financials
PeriodQ2 FY2026
Published
Gilead Sciences reported $7.80 billion in total revenues for Q2 FY2026, the quarter ended June 30, 2026, up 10.2% from a year earlier, with product sales of $7.63 billion, up 8.1%, but posted a net loss of $10.50 billion, or $8.45 per diluted share. The loss was driven mainly by $11.18 billion of acquired in-process research and development charges on three acquisitions that closed during the quarter, expensed at once rather than capitalized, and by a further $1.75 billion impairment that wrote a lung cancer intangible to zero. Underneath those charges the commercial business grew, led by HIV, where product sales were $5.69 billion, up 11.9%.
| Metric | Amount | vs. year ago |
|---|---|---|
| Revenue | $7,803,000,000 | up 10.2% |
| Net income | -$10,496,000,000 | swung from $1.96 billion |
| Diluted EPS | -$8.45 | swung from $1.56 |
| Product sales | $7,627,000,000 | up 8.1% |
| HIV product sales | $5,693,000,000 | up 11.9% |
| Acquired IPR&D charges | $11,183,000,000 | |
| IPR&D impairment | $1,750,000,000 |
Company details
| Name | Gilead Sciences, Inc. |
|---|---|
| Ticker | GILD |
| CIK | 0000882095 |
| Exchange | Nasdaq |
| State | California |
| Incorporation | Delaware |
| SIC | 2836 |
| Office | Life Sciences |
| Industry | Biological Products, (No Diagnostic Substances) |
| Latest period covered | Q2 FY2026, ended 2026-06-30, 10-Q, accession 0000882095-26-000031 |
| Fiscal year end | 12/31 (MM/DD) |
| Next expected filing | 10-Q around 2026-11-03 (predicted) |
Data files
- Financial statementsPage Annual financial statements plus the latest quarter: income statement, balance sheet, cash flow. Actual dollars, actual shares. Sourcing notes and uncertainties included.
- 10-K and 10-Q summaryPage Qualitative synthesis of the latest 10-K + 10-Q: business, risk factors (quarter-over-quarter changes flagged), MD&A, legal proceedings, subsequent events.
- 8-K filings and eventsPage Digest of material 8-K filings: earnings headlines, management changes, capital-return and financing actions, governance. SEC accession numbers cited throughout.
FAQ · Gilead Sciences Q2 FY2026
Did Gilead lose money in Q2 FY2026?
Yes. Gilead Sciences posted a net loss of $10.50 billion for Q2 FY2026, the quarter ended June 30, 2026, and a diluted loss per share of $8.45, against net income of $1.96 billion and diluted earnings per share of $1.56 in the same quarter a year earlier.
Why did Gilead report a loss in Q2 FY2026?
Gilead Sciences recorded $11.18 billion of acquired in-process research and development charges in Q2 FY2026 on three acquisitions that closed during the quarter. Those charges are expensed immediately rather than carried on the balance sheet, and together with an in-process research and development impairment on a discontinued lung cancer program they are the main reason the quarter ended in a net loss of $10.50 billion even as revenue rose.
How much revenue did Gilead report in Q2 FY2026?
Gilead Sciences reported $7.80 billion in total revenues for Q2 FY2026, the quarter ended June 30, 2026. That is up 10.2% from $7.08 billion in the same quarter a year earlier, and product sales were $7.63 billion, up 8.1%, with the rest of the increase coming from previously constrained revenue recognized on a sale of intellectual property.
How big is Gilead's HIV business?
HIV medicines remain the core of Gilead Sciences, with product sales of $5.69 billion in Q2 FY2026, up 11.9% from $5.09 billion a year earlier. That is the largest of the company's therapeutic franchises and the bulk of its total revenues of $7.80 billion.
Where can I get Gilead Sciences, Inc. (GILD) financial data in machine-readable form?
Ticker Scout publishes Gilead Sciences, Inc.'s financial statements as JSON at https://tickerscout.ai/gild/financials.json, free, with no API key and no signup. The 10-K and 10-Q narrative and the 8-K events digest are published as Markdown at https://tickerscout.ai/gild/narrative.md and https://tickerscout.ai/gild/events.md. Gilead Sciences, Inc.'s SEC CIK is 0000882095. Every figure cites the SEC accession number it came from, so it can be checked against sec.gov.
When does Gilead Sciences, Inc. (GILD) next file with the SEC?
Gilead Sciences, Inc. (GILD) is expected to file its next Form 10-Q with the SEC on or around November 3, 2026. That date is a projection rather than a company-announced date: it is derived from Gilead Sciences, Inc.'s own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 10-Q for Q2 FY2026, the period ended 2026-06-30, SEC accession 0000882095-26-000031.
Related companies
How this page was built
This page was built from Gilead Sciences, Inc.'s own filings with the SEC, read one at a time, and nothing on it is taken from a pre-tagged dataset, a data vendor or another website. The figures are on the company's own fiscal calendar and in actual dollars, as the filings report them. Where the filings do not support a figure, the record says so instead of reporting a zero; this period names four such gaps.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Data extracted from SEC filings (accession numbers cited in each file). The undated URLs hold the latest period and are replaced in place each quarter; every period also stays published at its own dated URL, which never changes. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.